Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AAM
AA Mission Acquisition
$10.66
+0.2%		$10.67
$10.29
▼
$10.89
$468.72M-0.0656,125 shs7,987 shs
SURE
AdvisorShares Insiders Advantage ETF
$148.66
+0.2%		$149.26
$119.19
▼
$153.29
$56.49M0.92393 shs232 shs
TEK
iShares Technology Opportunities Active ETF
$40.40
-1.9%		$39.29
$26.72
▼
$43.85
$43.63M1.985,177 shs1,980 shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$52.95
$51.03
$2.65
▼
$53.19
$6.12B-0.374.84 million shs6.35 million shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AAM
AA Mission Acquisition
0.00%0.00%0.00%0.00%+1.23%
SURE
AdvisorShares Insiders Advantage ETF
+0.17%+0.96%+0.43%-0.07%+24.74%
TEK
iShares Technology Opportunities Active ETF
-1.92%-3.76%+4.23%+2.59%+31.34%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
0.00%0.00%0.00%0.00%+549.69%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AAM
AA Mission Acquisition
$10.66
+0.2%		$10.67
$10.29
▼
$10.89
$468.72M-0.0656,125 shs7,987 shs
SURE
AdvisorShares Insiders Advantage ETF
$148.66
+0.2%		$149.26
$119.19
▼
$153.29
$56.49M0.92393 shs232 shs
TEK
iShares Technology Opportunities Active ETF
$40.40
-1.9%		$39.29
$26.72
▼
$43.85
$43.63M1.985,177 shs1,980 shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$52.95
$51.03
$2.65
▼
$53.19
$6.12B-0.374.84 million shs6.35 million shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AAM
AA Mission Acquisition
0.00%0.00%0.00%0.00%+1.23%
SURE
AdvisorShares Insiders Advantage ETF
+0.17%+0.96%+0.43%-0.07%+24.74%
TEK
iShares Technology Opportunities Active ETF
-1.92%-3.76%+4.23%+2.59%+31.34%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
0.00%0.00%0.00%0.00%+549.69%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AAM
AA Mission Acquisition
1.00
SellN/AN/A
SURE
AdvisorShares Insiders Advantage ETF
2.58
Moderate Buy$148.66N/A
TEK
iShares Technology Opportunities Active ETF
2.85
Moderate Buy$40.40N/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2.27
Hold$55.144.13% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AAM
AA Mission Acquisition
N/AN/AN/AN/AN/AN/A
SURE
AdvisorShares Insiders Advantage ETF
N/AN/AN/AN/AN/AN/A
TEK
iShares Technology Opportunities Active ETF
N/AN/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/A$9.70 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AAM
AA Mission Acquisition
N/AN/AN/AN/AN/AN/AN/AN/AN/A
SURE
AdvisorShares Insiders Advantage ETF
N/AN/A14.46N/AN/AN/AN/AN/AN/A
TEK
iShares Technology Opportunities Active ETF
N/AN/A43.98N/AN/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$96.21M-$1.03N/AN/AN/AN/A-20.02%-19.37%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AAM
AA Mission Acquisition
N/AN/AN/AN/AN/A
SURE
AdvisorShares Insiders Advantage ETF
$1.290.87%N/AN/AN/A
TEK
iShares Technology Opportunities Active ETF
$0.471.16%N/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AAM
AA Mission Acquisition
N/AN/AN/A
SURE
AdvisorShares Insiders Advantage ETF
N/AN/AN/A
TEK
iShares Technology Opportunities Active ETF
N/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/A
62.41
62.41

Institutional Ownership

CompanyInstitutional Ownership
AAM
AA Mission Acquisition
N/A
SURE
AdvisorShares Insiders Advantage ETF
N/A
TEK
iShares Technology Opportunities Active ETF
N/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
98.26%

Insider Ownership

CompanyInsider Ownership
AAM
AA Mission Acquisition
21.54%
SURE
AdvisorShares Insiders Advantage ETF
N/A
TEK
iShares Technology Opportunities Active ETF
N/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
1.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
AAM
AA Mission Acquisition
N/A43.97 million34.50 millionN/A
SURE
AdvisorShares Insiders Advantage ETF
N/A380,000N/ANot Optionable
TEK
iShares Technology Opportunities Active ETF
N/A1.08 millionN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
40115.52 million113.79 millionNot Optionable

Recent News About These Companies

Merck cuts 2026 profit forecast on Terns acquisition charges
August 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/merck-cuts-2026-profit-forecast-120742934.html
Terns charge tips Merck into a second-quarter loss as sales rise 5%
August 4, 2026  |  thepharmaletter.comT
How The Merck (MRK) Investment Story Is Shifting With Terns Deal And Oncology Updates
May 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/merck-mrk-investment-story-shifting-201652191.html
Merck completes acquisition of Terns Pharmaceuticals
May 6, 2026  |  pharmabiz.comP
MSD (Merck) to acquire Terns Pharmaceuticals in USD 6.7 billion deal
May 6, 2026  |  pharmiweb.comP
Merck adds to cancer drug portfolio with new acquisition
May 5, 2026  |  wfmz.comW
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
May 5, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260505216715/en/Merck-Completes-Acquisition-of-Terns-Pharmaceuticals-Inc./
Merck's Keytruda Surge: A Boost Amid Acquisition Costs
April 30, 2026  |  devdiscourse.comD
Merck still sees ‘compelling’ outlook for Terns leukemia drug
April 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/merck-still-sees-compelling-outlook-122100648.html
Oppenheimer downgrades Terns Pharmaceuticals (TERN)
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/oppenheimer-downgrades-terns-pharmaceuticals-tern/ar-AA21T8IK
Terns Pharmaceuticals gets FDA breakthrough status for leukemia drug
April 27, 2026  |  investing.comhttps://www.investing.com/news/stock-market-news/terns-pharmaceuticals-gets-fda-breakthrough-status-for-leukemia-drug-93CH-4638656
Terns Pharmaceuticals Gets Breakthrough Designation for Leukemia Treatment
April 27, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/terns-pharmaceuticals-gets-breakthrough-designation-for-leukemia-treatment-19cabee6
Buy, Sell or Hold MRK Stock With Q1 Earnings Around the Corner?
April 27, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2908217/buy-sell-or-hold-mrk-stock-with-q1-earnings-around-the-corner?cid=cs-stocknewsapi-ft-analyst_blog|most_popular_stocks-2908217
Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia
April 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/27/3281592/0/en/terns-pharmaceuticals-announces-fda-breakthrough-therapy-designation-granted-to-tern-701-for-certain-patients-with-chronic-myeloid-leukemia.html
Pharma giants see trial wins, EU approvals, and M&A progress
April 24, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/pharma-giants-see-trial-wins-eu-approvals-and-m-a-progress/gm-GMFEEDB182
Merck’s $6.7B Terns deal clears antitrust review
April 24, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/merck-s-67b-terns-deal-clears-antitrust-review/gm-GMF12FE66E
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS) and Terns Pharmaceuticals (TERN)
April 21, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/GUTS/pressreleases/984947/analysts-offer-insights-on-healthcare-companies-fractyl-health-inc-guts-and-terns-pharmaceuticals-tern/
Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERN
April 10, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260410403986/en/terns-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-terns-pharmaceuticals-inc.---tern/
Why Terns Pharmaceuticals Stock Rocked the Market in March
April 8, 2026  |  fool.comhttps://www.fool.com/investing/2026/04/08/why-terns-pharmaceuticals-stock-rocked-the-market/
Terns rebuffed a higher bid before selling to Merck
April 7, 2026  |  biopharmadive.comB

Media Sentiment Over Time

Top Headlines

View All Headlines
Adobe logo displayed on a wall behind an office desk with a laptop, notebook, and pens.
Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
By Dan Schmidt | September 14, 2026
Wood-framed house under construction in a residential neighborhood, with lumber stacked nearby and completed homes in the background.
Homebuilders Are Down for the Year, Is Wall Street in Denial?
By Chris Markoch | September 16, 2026
Laptop displaying the Hims & Hers logo beside a gavel, pill bottle, and declining stock chart with the US Capitol.
Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
By Jessica Mitacek | September 24, 2026
Kalshi and Polymarket logos beside a smartphone showing a prediction market on the Chiefs winning the Super Bowl, with a football in the background.
Want Private-Market Access to Kalshi and Polymarket? Try This ETF
By Jessica Mitacek | October 8, 2026
Lennar logo overlaid on a residential neighborhood with completed homes and houses under construction at sunset.
Lennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
By Thomas Hughes | September 18, 2026

AA Mission Acquisition NYSE:AAM

AA Mission Acquisition Corp. engages in the acquisition and merge of companies. It was founded on February 9, 2024 and is headquartered in The Woodlands, TX.

AdvisorShares Insiders Advantage ETF NYSEARCA:SURE

$148.66 +0.25 (+0.17%)
Closing price 10/12/2026 04:10 PM Eastern
Extended Trading
$148.67 +0.01 (+0.00%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

The AdvisorShares Insider Advantage ETF (SURE) is an exchange-traded fund that mostly invests in total market equity. The fund is an actively managed portfolio of US stocks selected using a proprietary model that follows insider buying and stock buyback strategies. SURE was launched on Sep 1, 2022 and is managed by AdvisorShares.

iShares Technology Opportunities Active ETF NYSEARCA:TEK

$40.40 -0.79 (-1.92%)
Closing price 10/12/2026 04:10 PM Eastern
Extended Trading
$40.42 +0.02 (+0.04%)
As of 10/12/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

The iShares Technology Opportunities Active ETF (TEK) is an exchange-traded fund that mostly invests in information technology equity. The fund is actively managed, investing in US and non-US technology companies across all market capitalizations. The fund aims for long-term growth of capital, focusing on firms with rapid growth potential in the industry TEK was launched on Oct 21, 2024 and is issued by BlackRock.

Terns Pharmaceuticals stock logo

Terns Pharmaceuticals NASDAQ:TERN

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas